Highlights of This Issue 2309

THERAPEUTIC DISCOVERY

2311 Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage
Jessica J. Gierut, Priya S. Mathur, Wenjun Bie, Jin Han, and Angela L. Tyner

2321 Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Nathan C. Dolloff, Joshua E. Allen, David T. Dicker, Nicole Aqui, Dan Vogl, Jozef Malysz, Giampaolo Talamo, and Wafik S. El-Deiry

2331 In Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer
Chunqing Guo, Huanfa Yi, Xiaofei Yu, Daming Zuo, Jie Qian, Gary Yang, Barbara A. Foster, John R. Subjeck, Xiaolei Sun, Ross B. Mikkelson, Paul B. Fisher, and Xi Yang-Wang

2342 Inhibition of Monocarboxylate Transporter 2 Induces Senescence-Associated Mitochondrial Dysfunction and Suppresses Progression of Colorectal Malignancies In Vivo
Inkyoung Lee, Sook-Ja Lee, Won Ki Kang, and Chaehwa Park

2352 Ceramide–Antiestrogen Nanoliposomal Combinations—Novel Impact of Hormonal Therapy in Hormone-Insensitive Breast Cancer
Samy A.F. Morad, Jonathan C. Levin, Sriram S. Shannugavelandy, Mark Kester, Gemma Fabrias, Carmen Bedia, and Myles C. Cabot

2362 Smoking Induces Epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Nagaraj S. Nagathihalli, Pierre P. Massion, Adriana L. Gonzalez, Pengcheng Lu, and Pran K. Datta

2373 Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
Kristin Pietschmann, Hella Anna Bolck, Marc Buchwald, Steffi Spielberg, Harald Polzer, Karsten Spiekermann, Gesine Bug, Thorsten Heinzel, Frank-Dietmar Böhmer, and Oliver H. Krämer

2384 Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Mona Samy, Charles-Henry Gattoilliat, Frédéric Pendino, Josette Hillion, Eric Nguyen, Sophie Bombard, Sêtha Douc-Rasy, Jean Bénard, and Evelyne Ségal-Bendirdjian

2394 Mechanism of Drug Efficacy Within the EGF Receptor Revealed by Microsecond Molecular Dynamics Simulation
Shunzhou Wan, David W. Wright, and Peter V. Coveney

2401 Deficient DNA Damage Signaling Leads to Chemoresistance to Cisplatin in Oral Cancer
Ling Wang, Adam J. Mosel, Gregory G. Oakley, and Aimin Peng

2410 MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer
Zhenwei Zhang, Xuemei Zhang, Kam Newman, and Xinyuan Liu

PRECLINICAL DEVELOPMENT

2419 Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth
Ruchi Bansal, Tushar Tomar, Arne Östman, Klaas Poelstra, and Jai Prakash

2429 Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor-Targeted Therapy
Atul Bedi, Xiaofei Chang, Kimberly Noonan, Vui Pham, Rishi Bedi, Elana J. Fertig, Michael Considine, Joseph A. Califano, Ivan Borrello, Christine H. Chung, David Sidransky, and Rajani Ravi

Contents

The Journal of Cancer Drug Discovery & Preclinical Development

November 2012 • Volume 11 • Number 11

www.aacrjournals.org
2440 O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Manik Chahal, Bassam Abdulkarim, Yaoxian Xu, Marie-Christine Guiot, Jacob C. Easaw, Nicolas Stifani, and Siham Sabri

2451 Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
De-Kuan Chang, Jianhua Sui, Shusheng Geng, Asli Muavfak, Mei Bai, Robert C. Fuhlbrigge, Agnes Lo, Anuradha Yanmanuru, Luke Hubbard, Jared Sheehan, James J. Campbell, Quan Zhu, Thomas S. Kupper, and Wayne A. Marasco

2462 Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas

2473 Stromal Platelet-Derived Growth Factor Receptor α (PDGFRA) Provides a Therapeutic Target Independent of Tumor Cell PDGFRA Expression in Lung Cancer Xenografts
David E. Gerber, Puja Gupta, Michael T. Dellinger, Jason E. Toombs, Michael Peyton, Inga Duignan, Jennifer Malaby, Timothy Bailey, Colleen Burns, Rolf A. Brekken, and Nick Loizos

2483 Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents

2495 8-Amino-Adenosine Activates p53-Independent Cell Death of Metastatic Breast Cancers
Alla Polotskaia, Sandy Hoffman, Nancy L. Krett, Mala Shanmugam, Steven T. Rosen, and Jill Bargonetti

2505 Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma
Devin G. Roller, Mark Axelrod, Brian J. Capaldo, Karin Jensen, Aaron Mackey, Michael J. Weber, and Daniel Gioeli

2516 A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXC4-Expressing Melanoma Cells Due to Enhanced Serum Stability
Tomonori Takekoshi, Joshua J. Ziarek, Brian F. Volksman, and Sam T. Hwang

MOLECULAR MEDICINE IN PRACTICE

2526 Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

SPOTLIGHTS ON CLINICAL RESPONSE

2535 Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component
Paul K. Paik, Anna M. Varghese, Camelia S. Sima, Andre L. Moreira, Marc Ladanyi, Mark G. Kris, and Natasha Rekhtman

2541 Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Vivek Subbiah, Robert E. Brown, Jamie Buryane, Jonathan Trent, Avi Ashkenazi, Roy Herbst, and Razelle Kurzrock
ABOUT THE COVER

May-Grünwald-Giemsa staining of IGR-N-91 neuroblastoma cells transduced with a dominant-negative (DN) variant of the catalytic subunit of the human telomerase (hTERT). Despite the use of high dose chemotherapy, stage 4 neuroblastoma patients have a dismal outcome, showing a need of new therapeutic approaches in these patients. A new link between telomerase biology and malignant neuroblast cell fate is discovered. Indeed, DN-hTERT transduction in a stage 4 neuroblastoma cell line promotes a switch from a neuronal to a substrate adherent phenotype and regulates key genes, leading to the loss of the malignant behavior of neuroblasts, thereby sensitizing them to anticancer drugs. Therefore, this finding has important implications in the development of novel strategies for neuroblastoma therapeutic management. For details, see article by Samy and colleagues on page 2384.
Molecular Cancer Therapeutics

11 (11)

Mol Cancer Ther 2012;11:2309-2546.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.